Novel Endpoint Selection for Rare Disease Trials: Regulatory Acceptance Criteria
Novel Endpoint Selection for Rare Disease Trials: Regulatory Acceptance Criteria Choosing Meaningful Endpoints in Rare Disease Trials: A Regulatory Perspective Understanding the Importance of Novel Endpoints in Rare Disease Research In traditional drug development, endpoints are well-established and standardized based on decades of clinical data. However, rare disease trials often lack validated endpoints due to…
Read More “Novel Endpoint Selection for Rare Disease Trials: Regulatory Acceptance Criteria” »